Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Non-Current Assets (2016 - 2026)

United Therapeutics' Non-Current Assets history spans 17 years, with the latest figure at $4.2 billion for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 19.7% to $4.2 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $15.9 billion, a 22.81% increase, with the full-year FY2025 number at $4.2 billion, up 19.7% from a year prior.
  • Non-Current Assets hit $4.2 billion in Q4 2025 for United Therapeutics, up from $3.9 billion in the prior quarter.
  • Over the last five years, Non-Current Assets for UTHR hit a ceiling of $4.2 billion in Q4 2025 and a floor of $780.9 million in Q4 2021.
  • Historically, Non-Current Assets has averaged $2.9 billion across 5 years, with a median of $3.1 billion in 2024.
  • Biggest five-year swings in Non-Current Assets: crashed 68.1% in 2021 and later surged 226.24% in 2024.
  • Tracing UTHR's Non-Current Assets over 5 years: stood at $780.9 million in 2021, then increased by 13.16% to $883.7 million in 2022, then increased by 21.06% to $1.1 billion in 2023, then surged by 226.24% to $3.5 billion in 2024, then rose by 19.7% to $4.2 billion in 2025.
  • Business Quant data shows Non-Current Assets for UTHR at $4.2 billion in Q4 2025, $3.9 billion in Q3 2025, and $4.1 billion in Q2 2025.